Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO)
(10% Negative) Imago BioSciences, Inc. (IMGO) Announces Delay in life Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review
📋 Imago BioSciences, Inc. (IMGO) - Clinical Trial Update
Filing Date: 2022-05-12
Accepted: 2022-05-12 10:39:11
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
Structured Data: